Landau Jeffrey B 4
4 · CytomX Therapeutics, Inc. · Filed Sep 22, 2023
Insider Transaction Report
Form 4
Landau Jeffrey B
Chief Business Officer
Transactions
- Award
Common Stock
[F1][F2]2023-09-20+11,250→ 80,498 total - Sale
Common Stock
[F3][F2]2023-09-22$1.30/sh−4,119$5,356→ 76,379 total
Holdings
- 4,500(indirect: By IRA)
Common Stock
- 3,180(indirect: By IRA)
Common Stock
Footnotes (3)
- [F1]Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
- [F2]Includes 52,205 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau|2023-09-22